Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Racotumomab - Recombio

Next Previous
X
Search
Drug Profile

Racotumomab - Recombio

Alternative Names: 1E10; 1E10 anti-idiotype vaccine therapy; Anti-idiotype antibody 1E10; Vaxira

Latest Information Update: 18 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Center of Molecular Immunology
  • Developer Center of Molecular Immunology; Elea; Innogene Kalbiotech; Recombio
  • Class Antineoplastics; Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Neuroblastoma
  • No development reported Colorectal cancer; Malignant melanoma; Solid tumours
  • Discontinued Breast cancer; Small cell lung cancer

Most Recent Events

  • 16 Apr 2021 Racotumomab is still in phase II trial for Neuroblastoma (In children, In infants, Second-line therapy or greater)in Argentina (NCT02998983)
  • 16 Apr 2021 Discontinued - Phase-II for Breast cancer (Metastatic disease) in Cuba (Intradermal)
  • 16 Apr 2021 Discontinued - Phase-II for Small cell lung cancer in Cuba (Intradermal)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top